- Conditions
- Cancer
- Interventions
- Multi-Cancer Early Detection Test (Galleri®)
- Device
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 72
- States / cities
- Fort Smith, Arkansas • Auburn, California • Davis, California + 51 more
Location Directory
Clinical trials in Portland, Oregon
This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9381
Shown on this page
12
Current sort
Recently updated
Location scope
Portland, OR
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 865–876 of 9,381 matching trials in Portland, OR.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Sleep
- Interventions
- Manipulation of Sleep Duration
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 29 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
- Conditions
- Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
- Interventions
- Tovorafenib, Chemotherapeutic Agent
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 25 Years
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Suicide, Adolescent Behavior
- Interventions
- Solace
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 250 participants
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Interventions
- Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more
- Conditions
- Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
- Interventions
- Z1 Femoral Hip System
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Platte City, Missouri • Charlotte, North Carolina • Cleveland, Ohio + 2 more
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib, Dupilumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil, Placebo, Prednisone, Prednisolone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more
- Conditions
- Atrial Fibrillation
- Interventions
- Clinical Decision Support (CDS) tool
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- AZD2287, AZD2275, AZD2284
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Diego, California • Miami, Florida + 9 more